MLV

MLV initiated coverage on Yuma Energy, Inc. (NYSE: YUMA) with a Buy rating. The target price for Yuma Energy is set to $1.50. Yuma Energy shares have declined 83.30 percent over the past 52 weeks, while the S&P 500 index has gained 12.45 percent in the same period. Yuma Energy shares closed...

MLV upgraded Rose Rock Midstream, L.P. (NYSE: RRMS) to Buy. Rose Rock Midstream shares have gained 18.02% over the past 52 weeks, while the S&P 500 index has surged 14.02% in the same period. Rose Rock Midstream's shares closed at $46.38 in pre-market trading.

MLV initiated coverage on Agios Pharmaceuticals Inc (NASDAQ: AGIO) with a Buy rating and $123 price target. Analyst Arlinda Lee noted that “AGIO’s integrated metabolome and genome approach identifies novel targets and has produced 3 drug candidates targeting metabolic dysfunction in...

In a note released Thursday morning, the team at MLV upgraded shares of Starwood Hotels & Resorts Worldwide (NYSE: HOT) from Hold to Buy and raised the price target from $86 to $96. The team wrote, "Our upgrade is based on our view that an improving economic landscape in the Eurozone...

In a report released Thursday, MLV analyst Ryan Meliker downgraded LaSalle Hotel Properties (NYSE: LHO) from Buy to Hold, but increased its price target from $36 to $38 per share. Meliker claim LaSalle's RevPAR and EBITDA growth is below his preferred range within the company's sectors...

In a report published Friday, MLV analyst George B. Zavoico initiated coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and $4.50 price target. In the report, MLV noted, “We are initiating coverage of Pluristem Therapeutics based on accumulating, though early, evidence of...

In a report published Wednesday, MLV analyst Jonathan Petersen downgraded the rating on CapLease (NYSE: LSE) from Buy to Hold, but raised the price target to $8.50. In the report, MLV noted, “This morning, CapLease (LSE) and American Realty Capital Properties (ARCP) announced that ARCP has...

MLV initiated its coverage on Starwood Property Trust (NYSE: STWD) with a Buy rating and a price target of $25.50. MLV noted, "STWD's development of a “recurring” lending business, which has already originated or acquired over $5B of loans over the past three years. STWD's industry leading...

MLV initiated its rating on NorthStar Realty Finance (NYSE: NRF) with a Buy rating and a price target of $6.50 a share. MLV noted, "Our BUY rating on NRF is driven by the following thesis: NRF's differentiated business model consisting of complementary earnings streams which span real estate debt...

MLV initiated its coverage on Resource Capital Corporation (NYSE: RSO) with a Buy rating and a price target of $6. MLV commented, "Our BUY rating on RSO is driven by the following thesis: RSO's established real estate lending platform which focuses on bridge loans in the $10-$30M range, an area...

MLV initiates its coverage on Cytokinetics (NASDAQ: CYTK) with a Buy rating and a price target of $4 as the company approaches a pivotal stage in the development of CK-357 and Omecamtiv. MLV notes, "Through a unique molecular motors targeting approach, Cytokinetics, Inc. has successfully...

In a report issued earlier today, MLV & Co announced that it is initiating coverage on Crimson Exploration Inc. (NASDAQ: CXPO), giving the stock a Buy rating and setting a price target of $5.50. MLV went on to say in the report “Our NAV [Net Asset Value], based upon proved reserves, working...

In a report issued earlier today, MLV & Co announced that it is initiating coverage on Crimson Exploration Inc. (NASDAQ: CXPO), giving the stock a Buy rating and setting a price target of $5.50. MLV went on to say in the report “Our NAV [Net Asset Value], based upon proved reserves, working...

According to a research report published earlier today, MLV & Co. has increased Transcept Pharmaceuticals' (NASDAQ: TSPT) PT from $21 to $24. MLV & Co. said in the report, “As Transcept prepares to collect royalty revenue for the first time from sales of its insomnia drug Intermezzo® (...

MLV maintains its Buy rating on Curis (NASDAQ: CRIS) and raises its price target to $10 from $8.50 a share as the company is looking to increase profitability sooner rather than later on approval of Erivedge from the FDA. MLV comments, "Yesterday, Curis announced FDA approval of Erivedge™ (...